Go Pro
OTCMKTS:DGNOF

DIAGNOS Q2 2025 Earnings Report

DIAGNOS logo
$0.34 0.00 (-0.47%)
As of 03:34 PM Eastern

DIAGNOS EPS Results

Actual EPS
-$0.01
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

DIAGNOS Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

DIAGNOS Announcement Details

Quarter
Q2 2025
Time
During Market Hours
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

DIAGNOS' next earnings date is estimated for Tuesday, December 1, 2026, based on past reporting schedules.

Conference Call Resources

DIAGNOS Earnings Headlines

Bank of America: 'Digital Dollar Inevitable'
Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the digital dollar. They gave us the timeline… 2025 to 2030. We're in that window right now. Once the digital dollar launches, every transaction you make will be tracked. Your spending could be controlled. Your accounts could be frozen. Over 4,500 investors have already used this legal backdoor to hold assets CBDCs can't freeze and generate yields the Federal Reserve can't touch.tc pixel
See More DIAGNOS Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like DIAGNOS? Sign up for Earnings360's daily newsletter to receive timely earnings updates on DIAGNOS and other key companies, straight to your email.

About DIAGNOS

DIAGNOS (OTCMKTS:DGNOF) is a Canadian healthcare technology company focused on the early detection of medical conditions through artificial intelligence, image processing and telemedicine. The company develops and commercializes tools designed to help healthcare providers identify disease at an earlier stage and support access to diagnostic services.

Its principal platform, CARA (Computer Assisted Retinal Analysis), analyzes retinal images to assist with the screening of conditions such as diabetic retinopathy and other eye diseases. DIAGNOS has also developed related screening and remote-care capabilities intended to support patient assessment in clinics, pharmacies and other healthcare settings.

Founded in 1998 and headquartered in Brossard, Quebec, DIAGNOS has pursued commercial and screening initiatives in Canada and international markets. The company’s solutions are designed for use by healthcare organizations seeking scalable, technology-assisted screening and telemedicine services.

View DIAGNOS Profile